GeniusAb™ is an innovative fully human single-domain antibody platform focused on the efficient and cost-effective screening and development of therapeutic single-domain antibodies. These single-domain antibodies have been widely used in the field of biomedicine because of their unique properties.

The primary purpose of single-domain antibody (sdAb) screening is to identify sdAbs that bind specifically to the target antigen. This process involves screening a large library of antibody candidates to identify those with desired binding properties. The antibody screening platform is able to identify sdAbs with high affinity, specificity, and functional properties, making it a valuable tool in the research, diagnostic, and therapeutic fields.

Due to their small size, single-domain antibodies are able to penetrate tissue better, providing more effective targeted therapies. In addition, single-domain antibodies also have excellent stability and strong affinity, can recognize multiple targets, and relatively low immunogenicity makes them have better safety in clinical applications. Single-domain antibodies are known for their small size and excellent tissue penetration, combined with high stability, strong affinity, and diverse target recognition capabilities. In addition, its low immunogenicity and easy modification give it wide application potential in the biomedical field.

In order to effectively reduce the cost and time to discover novel therapeutic single-domain antibodies from species such as camels and sharks, Protheragen has introduced an innovative solution - GeniusAb™ mice. These mice were genetically engineered to produce fully human, single-domain antibodies. Based on the GeniusAb™ mice platform, Protheragen has successfully eliminated the need for traditional in vitro humanization, thereby optimizing the antibody screening and production process, making the entire process more efficient and cost-effective.

The antibodies derived from GeniusAb™ mice demonstrated excellent stability, good solubility, low immunogenicity, and desirable properties compatible with downstream manufacturing processes. These excellent properties not only improve the biological performance of the antibodybut also lay a solid foundation for the subsequent application. Stability ensures the activity of the antibody during storage and use, while good solubility increases the available concentration of the antibody, facilitating subsequent experiments and production processes. The low immunogenicity makes these antibodies less likely to trigger an immune response when used in the body, reducing the risk of potential adverse reactions. In addition, compatibility with downstream manufacturing processes enables efficient and stable large-scale preparation in industrial production. These important properties are essential for the successful development and commercialization of antibot-based therapeutics or diagnostic reagents and are therefore of critical value in modern biomedical research and applications.

Protheragen has established a fully human single-domain antibody platform and antibody screening platform specifically designed to advance the preparation, discovery, and development of sdAbs. The platform leverages a variety of cutting-edge antibody preparation and screening technologies to meet your specific research needs. Protheragen is committed to pushing the boundaries of single-domain antibody screening technology and is focused on driving innovation and developing new ways to transform this field. At the same time, Protheragen's professional advisory team will take care to answer your questions during the purchase process.